logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2020 — Beyond androgen receptor inhibition in metastatic castration-resistant prostate cancer

First-line abiraterone, ipatasertib leads to better clinical outcomes vs androgen receptor inhibition alone.